Elevance Health Inc. (NYSE: ELV)
Q2 2022 Earnings Call
Jul 20, 2022, 8:30 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Ladies and gentlemen, thank you for standing by, and welcome to Anthem's second quarter earnings conference call. [Operator instructions] As a reminder, today's conference is being recorded. I would now like to turn the conference over to the company's management. Please go ahead.
Steve Tanal -- Vice President, Investor Relations
Good morning, and welcome to Elevance Health second quarter 2022 earnings call. This is Steve Tanal, vice president of investor relations. And with us this morning on the earnings call are Gail Boudreaux, president and CEO; John Gallina, our CFO; Peter Haytaian, president of Carelon; Morgan Kendrick, president of our commercial and specialty business division; and Felicia Norwood, president of our government business division. Gail will begin the call with a brief discussion of the quarter and recent progress against our strategic initiatives.
John will then discuss our financial results and outlook in greater detail. After our prepared remarks, the team will be available for Q&A. During the call, we will reference certain non-GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are available on our website, elevancehealth.com.
We will also be making some forward-looking statements on this call. Listeners are cautioned that these statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Elevance Health. These risks and uncertainties can cause actual results to differ materially from our current expectations. We advise listeners to carefully review the risk factors discussed in today's press release and in our quarterly filings with the SEC.
I will now turn the call over to Gail.
Gail Boudreaux -- President and Chief Executive Officer
Thanks, Steve, and good morning, everyone. Today, we're pleased to share that Elevance Health delivered another strong quarter. In the second quarter, GAAP earnings per share was $6.79, and we grew adjusted earnings per share over 14% to $8.04. Based on our results in the first half of the year and the momentum in our business, we've increased our full year adjusted earnings guidance to greater than $28.70 per share, representing growth of at least 13.9% off of the adjusted baseline we provided at the beginning of the year.